Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia, improved biomarkers and cognitive outcomes in patients with dementia with Lewy bodies (DLB) in a phase 2 randomized, double-blind, placebo-controlled trial. The findings align with an earlier study that showed possible disease-modifying effects of nilotinib in patients with ...
Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved